Amidst an ocean of opportunity that covers much of pharmacology, we focused our drug development on expanding the market for Keytruda, the best-selling cancer drug. In that pursuit, we have demonstrated that our platform can deliver enhanced monoclonal antibody, small molecule, cytokine, and protein drugs that generate significant improvements in anti-PD-1 performance.
These demonstrations are steppingstones toward improving the value of innumerable monoclonal antibody drugs. Beyond this, proprietary conjugates can be made with proteins, cytokines, nucleic acids, peptides, small molecules and antibody drug conjugates, as well as larger drug vectors like oncolytic viruses and lipid nanoparticles.
In short, our platform can produce an endless stream of proprietary pharmaceuticals.